Tag archive for ‘Opko Health Inc. (NYSE: OPK; TASE: OPK)’
Gali Weinreb On Tuesday, December 16th, 2014

Pfizer buys Israel-developed hormone drug from Opko

– Pfizer will pay $295 million for the growth hormone treatment and up to $275 million in milestone payments, and royalties. Pfizer Inc. (NYSE: PFE) has acquired the development and commercialization More...

Moshe Golan On Wednesday, April 16th, 2014

Opko health turns Prolor Biologics into Israeli R&D, investment arm

– Chairman Phillip Frost: We have big plans for Opko Biologics. – Opko Health Inc. (NYSE: OPK; TASE: OPK) has renamed Prolor Biotech, which it acquired for $480 million a year ago, as Opko More...

Gali Weinreb On Tuesday, March 4th, 2014

Opko Health Losses Triple

– Chairman and CEO Phillip Frost: From an R&D perspective, all our programs are progressing. – – – Opko Health Inc. (NYSE: OPK; TASE: OPK) reported higher full-year and fourth More...

Ilan Shavit On Tuesday, December 24th, 2013

Tesaro Reports Positive Phase III Results For Opko Nausea Drug

– The Adverse Event Profile for Rolapitant was Consistent with Earlier Clinical Trials. Preparations Continue in Support of Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration More...

Wordpress site Developed by Fixing WordPress Problems